Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut. by Mulcahy, R. T. et al.
Br. J. Cancer (1982) 45, 835
NITROSOUREA-MISONIDAZOLE COMBINATION CHEMOTHERAPY:
EFFECT ON KHT SARCOMAS, MARROW STEM CELLS AND GUT
R. T. MULCAHY, D. W. SIEMANN* AND R. M. SUTHERLANDt
From the Experinmental Therapeutics Division, Departments ofPathology, *tRadiology,
and *tRadiatioii Biology and Biophysics, University of Rochester Cancer Center,
Rochester, New York. 14642, U.S.A.
Received 23 November 1981 Aceepted 19 February 1982
Summary.-C3H/HeJ mice bearing i.m. transplanted KHT sarcomas were treated
with varying doses of either 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) or 2-{3-
(2-chloroethyl)-3-nitrosoureido}-D-glucopyranose (chlorozotocin; CHLZ) as single
agents or in combination with 1 mg/g of the chemical radiosensitizer, misonidazole
(MISO). Using an in vivo-in vitro tumour-excision assay, the administration of MISO
simultaneously with or 3 h after low doses of BCNU ( <20 mg/kg) was found to give a
dose-modification factor (DMF) of P165 relative to BCNU alone. At higher doses of
BCNU, there was less enhancement of cell kill. The DMF for tumour growth delay
was likewise dependent on BCNU dose, continuously decreasing with increasing
BCNU dose. In contrast, the anti-tumour activity of CHLZ, assessed by both clono-
genic cell survival and tumour-growth delay, was not signficantly enhanced by the
addition of MISO.
The enhancement of gastrointestinal toxicity and haematotoxicity by BCNU-
MISO combinations was assessed by LD50/7 and CFU-S assays, respectively. MISO
enhanced BCNU marrow toxicity by a factor of 1-2-1-3, whilst gut toxicity was
enhanced by a factor of 1-2.
RECENT demonstrations of hypoxic
tumour-cell chemoresistance have promp-
ted the design and evaluation of experi-
mental protocols combining commonly
used anti-tumour agents with nitroimi-
dazoles, which in addition to sensitizing
hypoxic cells to radiation, havebeenshown
to be preferentially cytotoxic to hypoxic
cells (review by Adams, 1981). Such
chemotherapeutic combinations have been
evaluated in several in vitro and in vivo
model systems and found to enhance the
effectiveness of many commonly used
alkylating agents (Sutherland et al., 1979;
Roizin-Towle & Hall, 1978; Rose et al.,
1980; Clement et al., 1980; Tannock,
1980a, b; Mulcahy et al., 1981; Siemann,
1981; Lawetal., 1981). Inspiteofencourag-
ing experimental results, combination
chemotherapy with nitroimidazole radia-
tion sensitizers will prove to be of thera-
peutic benefit only ifthe magnitude ofthe
enhanced tumour response exceeds the
enhancement of normal-tissue toxicities.
Clonogenic and tumour-growth delay
assays were therefore used in the current
study to assess the degree of dose modifi-
cation produced by two BCNU-MISO
treatment protocols. The magnitude of
tumour-response enhancement was then
compared to the dose modification pro-
duced for marrow stem cells, determined
by spleen-colony (CFU-S) assay (Till &
McCulloch, 1961) and for gastrointestinal
toxicity assayed by the LD50/7 technique.
For comparison with these BCNU
investigations, and similar studies with
CCNU (Siemann, 1981) the efficacy of
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combining MISO) with 2-{3-(2-chloroethyl)-
3-nitrosoureido}-D-glycopyranose (chloro-
zotocin; CHLZ) a recentlydevelopednitro-
sourea with anti-tumour activity and
reduced myelotoxicity (Schein et al.,
1978) was also determined.
MATERIALS AND MVlETHODS
Aninials and tumour systenm. All studies
wrere done using 8-12-week-old female C3H/
HeJ mice purchased from Jackson Labora-
tories, Bar Harbor, Maine. KHT sarcoma
cells (Kallman et al., 1967) were passaged in
vivo every 2 weeks, and prepared from
solid tumours by mechanical dissociation
(Thomson & Rauth, 1974). KHT tumour
cells (2 x 105) wvere injected i.m. into the right
limb. Animals were sorted and randomized
into the appropriate control and experi-
mental groups (7/group) when tumours had
grown to 0-2-0-4 g.
Drug treatmentt.-BCNU was initially dis-
solved in 100% ethanol at a concentration of
30 mg/ml. and then diluted to a final con-
centration of 1-5 mg/ml with physiological
saline immediately before injection. CHLZ
was dissolved directly in physiological saline
(1-0 mg/ml) immediately before injection.
MISOC was dissolved in phosphate-buffered
saline at a concentration of 20 mg/ml. All
drugs were administered i.p. MISO (1P0 mg/g
body weight) was administered either simul-
taneously with. or 3 h after nitrosourea
injection.
Tumour-yrowth delay. Tumour size w%vas
measured daily after drug treatment by
passing the tumour-bearing leg through a
series of holes of increasing diameter in a
Plexiglass rod. This measurement w%as then
converted to tumour weight, using a cali-
bration curve obtained by excising and
wNTeighing tumours of measured diameters
from the legs of untreated animals (Siemann
et al., 1977). Growth delay was then measured
as the time required for treated tumours to
grow to 4 times the initial treatment wveight
relative to that required for untreated
tumours.
Clonogenic cell survival. KHT sarcoma
cell-survival assavys were performed 22-24 h
after treatment. The mice wvere killed by
cervical dislocation, their tumours excised.
and a single-cell suspension prepared by a
combination of mechanical and enzymatic
dissociation procedures (Thomson & Rautlh.
1974). Twsro tumour,s were pooled for eachi
cell suspension. Appropriate cell dilutions
wsere mixed with lethally irradiated tumour
cells in 0.200 agar containing a-minimum
essential medium (o-MEM; Stanners et al..
1971) supplemented with 10% foetal calf
serum and plated into 24-well culture dishes.
In about 2 weeks. the surviving cells formed
colonies wvhich were counted using a dissect-
ing microscope. Tumour-cell survival after
treatment was calculated as the product of
the ratios of treated and untreated control
values of plating efficiency, tumour weight.
and cell yield/g tumour.
>Spleen-colony assay.-The spleen-colony
assay of Till & McCulloch (1961) was used to
assess marroA stem-cell (CFU-S) survival
24 h after exposure to BCNU or BCNU+
MISO. Recipient C3H/HeJ mice were exposed
to 15 Gy whole-body irradiation, adminis-
tered in 2 fractions of 10 and 5 Gy, 3 h apart.
Marrow" was flushed from the femurs, nucle-
ated cells counted, appropriate dilutions
prepared and injected i.v. into the irradiated
recipient mice. Eight or 9 days after cell
injection, the spleens -were harvested and the
numberofcoloniesdetermined. Mean stem-cell
survival and standard error were calculated
according to Blackett (1975).
Gastrointestinal toxicity. Gastrointestinal
toxicity was estimated by determining the
number of animals which died during 7 days
post-treatment. From these data. LD50/7
(lethal dose to 50% of the animals in 7 days)
and confidence limits were calculated by
fitting a logit bioassay (Berkson, 1955) and
using Scheffe's discrimination intervals
(Finney, 1978).
RESULTS
Tumour response
The efficacy of combining MISO with
either of 2 nitrosoureas, BCNU or CHLZ,
for the treatment of i.m. transplanted
KHT tumours, was assessed by tumour-
growth delay and clonogenic cell-survival
assays. The median number of days
required for KHT tumours to grow to 4
times their initial size for groups of 7
mice treated with BCNU alone, BCNU+
simultaneous MISO, or BCNU +MISO
3 h later, are shown in Fig. 1. After treat-
ment, with BCNU alone, median growth
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FiG. 1. The median tumour-growt(ldelay
according to BCNU dose for KHT tumour
tireated with BCNU alone (0) or with
I mg/g MISO simultaneously (A) or 3 h1
after BCNU (A). Each symbol represents
an individual experiment with 7 animals
per group. *, P < 005 by Mann-Whitney
Rank-Sum test. The curve for the BCNU
alone was fitted using a non-linear least-
squares method. The line through the data
for both simultaneous and delayed MISO
data was fitted by linear least-squares
analysis.
delay increased non-linearly with dose.
As previously reported (Tannock, 1980b;
Mulcahy et al., 1981; Siemann, 1981),
the growth of tumours treated with a
single 1 mg/g dose of MISO alone was not
significantly different from that of un-
treated tumours. When MISO was com-
bined either simultaneously with BCNU
or 3 h later, there was enhancement in the
median growth delay, particularly at the
lowest BCNU doses. Interestingly, the
growth-delay enhancement was similar
for both injection schedules. At BCNU
doses above - 10 mg/kg, the median growth
delay for both treatment combinations
increased linearly with BCNU dose. How-
ever, as a consequence of the curvilinear
BCNU dose-response curve, the dose-
modification factor (DMF, calculated from
the ratio of BCNU dose alone required to
produce a given growth delay and the
dose of BCNU required to produce the
same growth delay when combined with
MISO) for combination therapy pro-
gressively decreased with increasing doses
of BCNU, until BCNU treatments with
or without MISO were equally effective.
The clonogenic survival ofKHT tumour
cells treated in vivo with MISO or BCNU
and assayed in vitro 22-24 h after treat-
ment, is shown in Fig. 2A. After single-
agent treatment with BCNU, survival
decreased linearly with increasing BCNU
dose, up to a dose of 40 mg/kg (surviving
fraction of 1 x 10-4). At higher BCNU
doses still, there was a tail on the survival
curve, suggesting a relatively resistant
population of tumour cells. In contrast,
the cell-survival dose-response curve for
KHT tumour cells treated in vivo with
MISO alone was dominated by a large
shoulder, followed by a significant decrease
in cell survival only at doses > 1 mg/g.
Cell survival was similarly determined
after the in situ treatment of KHT
tumours with either of the two BCNU-
MISO injection schedules. As with growth-
delay enhancement, cell kill was equally
enhanced by MISO under both treatment
conditions (Fig. 2B, P>0.10). However,
at survival levels below 1 x 10-4, a
resistant tail on the survival curve was
evident after both combined-drug treat-
ments. By slope-ratio assay (Finney, 1978)
the DMF for the initial linear portion of
the survival curve, obtained by pooling
the results of both MISO-BCNU com-
binations, was found to be 1-65 (95%
limits 1-47-1-83). However, due to the
presence of a population of tumour cells
which are relatively resistant to BCNU
treatment (with ot without MISO) the
DMF by MISO progressively decreased at
BCNU doses > 20 mg/kg.
In a similar series of experiments, the
effect of treatment with CHLZ alone,
837R. T. MULCAHY, D. W. SIEMANN AND R. M. SUTHERLAND
MISO (mglg)
0.5 1.O 1.5 2.0
10 20 30 40 50 /0 20 30 40
BCNU (mglkg) BCNU (mg/kg)
FIG. 2.-Clonogenic cell survival for KHT tumours excised 22-24 h after treatment with (A) BCNU
(0) or MISO (A). (B) BCNU+ MISO administered simultaneously (A) or with MISO 3 h after
BCNU (A). The broken line is the curve for BCNU alone from (A). The combination treatments
produced a dose modification of 1-65 (95% limits 1-48-1-83) at survival levels > 10-4.
The linear portions of the BCNU and BCNU+MISO survival curves were fitted by linear least
squares analysis.
CHLZ combined with simultaneous MISO
or MISO 3 h later was assessed in the
KHT sarcoma by tumour-growth delay
(Fig. 3B). Tumour-cell survival (Fig. 3A)
was also determined after CHLZ alone or
CHLZ +simultaneous MISO. Itisapparent
from these studies that CHLZ is less
effective than BCNU in the KHT tumour
system, and that the anti-tumour activity
of this agent is not enhanced by the addi-
tion of MISO to the treatment protocol.
Since cell-kill enhancement was absent
for MISO combined with any dose of
CHLZ, tumour growth-delay assays were
only performed for MISO combined with
one dose ofCHLZ.
Normal-tissue response
In an attempt to estimate the potential
therapeutic benefit of combining a nitro-
imidazole with a conventional anti-
tumour agent, the enhancement of mar-
row and gastrointestinal toxicities by
BCNU-MISO treatment were compared
with the magnitude of the enhanced
tumour response. CFU-S survival was
measured by spleen-colony assay (Fig. 4).
DMFs of 1 2 and 1-3 (ratio of slopes from
linear least-squares fits) were obtained
when MISO was administered simul-
taneously with BCNU or 3 h later, respec-
tively. Gastrointestinal toxicity was en-
hanced similarly by these combinations.
The LD50/7 for mice treated with BCNU
alone was 83 mg/kg (95% limits 80-85).
This value was reduced by factors of 1.1
and 1 2 after simultaneous (LD50/7=
78 mg/kg, 95% limits 75-81) and delayed
MISO administration (LDmsV7 = 70 mg/kg,
limits 69-71). It should be noted however,
that significant enhancements in marrow
and gut toxicities were detected only at
doses of BCNU greater than those pro-
ducing significant enhancements of anti-
tumour activity (i.e. > 40 mg/kg).
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FIG. 3.-(A) Survival curve for KHT tumour cells treated in vivo with CHLZ alone (open symbols)
or combined with a simultaneous 1 mg/g dose of MISO (closed symbols). Different symbol shapes
are separate experiments. The curve through the data was drawn by eye. (B) Growth curves for
untreated KHT tumours (0) and tumours treated with 40 mg/kg CHLZ alone (X), CHLZ +
simultaneous MISO (A), or MISO 3 h after CHLZ (A). Each point represents the mean of 14
animals. Bars indicate s.e.
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FIG. 4. Marrow CFU-S survival 24 h after
treatment with BCNU (circles), simul-
taneous BCNU and MISO (triangles), or
MISO administered 3 h after BCNU
(squares). Open and closed symbols repre-
sent separate experiments. Data were
fitted by linear least-squares analysis.
Bars indicate s.e.
Drugfractionation
Because the DMF for tumour-growth
delay on combining BCNU and MISO
decreased rapidly with increasing BCNU
dose, the possibility of therapeutic benefit
appeared to be greater at lower BCNU
doses. A single series of experiments was
therefore designed to evaluate the feasi-
bility of fractionating BCNU and MISO
treatment. In these studies, the growth
delay produced on combining MISO with
3 small daily doses (10 mg/kg) of BCNU
was assessed, and compared to the delay
when MISO was combined with the same
total BCNU dose (30 mg/kg) in a single
treatment.
MISO was added to the fractionation
scheme either as a single 1-0 mg/g dose
on Day 0, or as 3 daily doses of 0 7 mg/g
each. In all cases, MISO and BCNU were
administered simultaneously. The results
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TABLE.-Efject of fractionated BCNI-MIISO treatment on the yrowu.th of KHT sarcomnas
:3()
10:
l'ime for mediaiL
ttumour to grow to
4 x starting size
3(NU A118() it ((lays)
---- 7 :3*5
mg/kg* 24 11
mg/kg 7 8
0(7 mg/g
(laily x 3
1 (0 mg/g
(lay I onlly
1 8
7 8
laily x :
10 mg/kg
laily x 3
10 mg/kg
(laity x 3
Confidence
interval (0 °,)
3-4 (88)
14)-12 (98)
7-'. (88)
7.5-9 (88)
8-9 (88)
* D)ata from previouts e?x)erlm(Ilts.
of these studies are shown in the Table.
Compared to a single 30 mg/kg dose of
BCNU, 3 daily doses of 1.0 mg/kg greatly
reduced the growth delay ofKHT tumours
(8 vs 11 days). The addition of a large
single dose or 3 smaller, daily doses of
MISO did not significantly enhance the
growth delay produced by BCNU fraction-
ation.
DISCUSSION
Using both growth delay and clono-
genic cell-survival assays, the anti-tumour
enhancement of combining the chemical
radiosensitizer MISO with two nitro-
soureas (BCNU and CHLZ) for the treat-
ment ofKHT tumours was compared with
the corresponding enhancement of gastro-
intestinal and marrow toxicities. In
tumour-growth delay studies with BCNU,
larger enhancements were achieved by
combining MISO with relatively low
BCNU doses (Fig. 1) and there was no
significant enhancement when MISO was
combined with large single doses ofBCNU.
Clonogenic-survival data suggest that the
differential enhancement at low doses may
arise from a small population BCNU-
resistant tumour cells which are equally
resistant to BCNU when combined with
MISO. The biphasic cell-survival curve
obtained with BCNU alone (Fig. 2A) is
similar to that reported by Lin &
Bruce (1972) for BCNU-treated KHTl'
tumouirs.
The striking similarity in degree of
enhancement produced by the 2 MISO-
BCNU combinations is of interest,, par-
ticularly in relation to pot,ential mechan-
isms. We previously suggested that, the
enhanced tumour response on combining
MISO and BCNU might be due to altered
phamacokinetics, ofeither MISO or BNCU
(Mulcahy et al., 1981). However, AMISO
pharmacokinetics in mice treated simul-
taneously with MISO and BCNU are not
significantly different from mice treated
with MISO alone (Mulcahy et al., unpub-
lished). Tannock has reported that serum
from mice treated simultaneously with
BCNU and MISO 30 min before killing
had activity against aerobic CHO cells
similar to that of serum from animals
treated with BCNU alone (Tannock,
1 980b). These data suggest that BCNU
pharmacokinetics are not substantially
altered by simultaneous treatment with
MISO. Furthermore, considering the short
half-life of BCNU in serum, it seems
unlikely that administration of MISO
3 h after BCNU could substantially alter
BCNU pharmacokinetics. In the light of
these considerations, it seems unlikely that,
pharmacokinetic changes are entirely
responsible for the enhanced tumour
response to chemotherapy with MISO
and BCNU under our administration
schedules.
In contrast to the modest tumour-
response enhancement when MISO is
combined with BCNU, and the markedl
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enhancement when MISO is combined
with CCNU (Siemann, 1981) the effective-
ness of the third structurally related
nitrosourea, CHLZ, was not significantly
modified (Fig. 3). It has recently been
suggested that the differential enhance-
ment of the anti-tumour effect of various
nitrosoureas by MISO might be corre-
lated with their carbamoylating activity
(Mulcahy, 1982). Carbamoylation has been
related to inhibition of the repair of sub-
lethal damage caused by alkylation
(Wheeler, 1976).
In conclusion, we have demonstrated
that the anti-tumour effect of BCNU, but
not of CHLZ, can be modestly enhanced
by combination with MISO. For BCNU,
the enhancement of tumour-growth delay
decreases rapidly to extinction with
increasing dose. Clonogenic cell-survival
data suggest that this effect may be due
to a population of tumour cells equally
resistant to BCNU and BCNU-MISO
combinations. Both MISO injection sched-
ules produced the same tumour responses,
whether assessed by growth delay or
clonogenic-cell survival. Normal-tissue
toxicities were also enhanced by the
MISO-BCNU combinations, but less than
in tumours treated with MISO and
relatively low-dose BCNU. However, two
simple dose-fractionation protocols, des-
igned to take advantage ofthis differential
enhancement at low BCNU doses, failed
to improve the tumour response.
These studies suggest that combination
chemotherapy of MISO with BCNU or
CHLZ may not significantly enhance
tumour response over norrnal-tissue res-
ponse, particularly at large BCNU doses.
Similar results for BCNU and MISO have
recently beenreportedbyTannock (1980b).
However, in spite of the poor enhance-
ment achieved with BCNU and the lack
of enhancement with CHLZ, studies com-
bining MISO with CCNU, and other
chemical alkylators, demonstrate that
this approach to combination chemo-
therapy may have significant therapeutic
potential, and therefore warrants con-
tinued investigation.
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